ClinicalTrials.gg
CompletedNCT00681356Updated May 4, 2009

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

A Phase 3 interventional study of 4975, 15 and 5 mg and Placebo Comparator in Total Knee Arthroplasty (Replacement), sponsored by Anesiva, Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2009-05-04.

Sponsored by Anesiva, Inc. · Phase 3, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement

Read the detailed description

The purpose of this study is to evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing primary unilateral total knee arthroplasty

02

Conditions studied

  • Total Knee Arthroplasty (Replacement)

Keywords

  • TKA
  • Total knee arthroplasty
  • Total knee replacement
  • Knee surgery
03

In context

Lead sponsor

Anesiva, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female aged 18 to 85 years with an (ASA) status of I, II, or III
  • Planning to undergo primary unilateral Total Knee Arthroplasty (TKA)

Key Exclusion Criteria:

  • A (BMI) greater than 43
  • Known bleeding disorder or is taking agents affecting coagulation preoperatively
  • Use of medications or a medical condition that in the investigator's opinion could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments
  • Diabetes mellitus with a known >9.5 or a history of prolonged uncontrolled diabetes
  • Previous knee arthroplasty (partial or total) of the same knee
  • Participated in another clinical trial within 30 days prior to the planned TKA surgery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
214 participants (estimated)

Study arms

  • Experimental
    1

    4975 - 15 mg

    Drug: 4975, 15 and 5 mg

  • Placebo comparator
    2

    Placebo

    Drug: Placebo Comparator

  • Experimental
    3

    4975 - truncated for Phase 3

    Drug: 4975 - 5 mg

Interventions

  • Drug4975, 15 and 5 mg

    Direct instillation into the surgical site

    Also known as: Adlea

  • DrugPlacebo Comparator

    Direct instillation into the surgical site

  • Drug4975 - 5 mg

    Direct instillation into the surgical site

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) measures of pain at prespecified times

    Time frame: Primary endpoint is 2 days (4-48 hours)

Secondary outcomes

  1. Other efficacy parameters, safety and tolerability of 4975

    Time frame: 42 Days or Early Termination

07

Study locations

25 sites
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Springhill Medical Center
    Mobile, Alabama 36608, United States
  • Hellen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Visions Clinical Research/Tucson Medical Center
    Tucson, Arizona 85712, United States
  • Glendale Adventist Medical Center - Lotus Clinical Research
    Glendale, California 91206, United States
  • Physicians Clinical Research Corporation
    Laguna Hills, California 92653, United States
  • Saddleback Memorial Medical Center/Accurate Clinical Trials
    Laguna Hills, California 92653, United States
  • Webster Orthopeadic Medical Group
    Oakland, California 94612, United States
  • UCSF-Mt. Zion Medical Center
    San Francisco, California 94115, United States
  • Orthopedic Associates of Hartford
    Hartford, Connecticut 06106, United States
  • Florida Hospital - Florida Research Associates, LLC
    DeLand, Florida 32720, United States
  • University of Miami, Miller School of Medicine
    Miami, Florida 33136, United States
  • Miami Institute for Medical Research
    Miami, Florida 33186, United States
  • Southeastern Clinical Research Consultants
    Orlando, Florida 32804, United States
  • Coastal Medical Research
    Port Orange, Florida 32127, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Ruxton Professional Center - Orthopaedic Associates
    Towson, Maryland 21204, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48085, United States
  • William Beaumont Hospital
    Troy, Michigan 48085, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Sewickley Valley Hospital
    Sewickley, Pennsylvania 15143, United States
  • Presbyterian Hospital of Dallas
    Dallas, Texas 75231, United States
  • Memorial City Hospital - Memorial Hermann Healthcare System
    Houston, Texas 77024, United States
08

References and documents

Publications

  • Hartrick CT, Pestano C, Carlson N, Hartrick S. Capsaicin instillation for postoperative pain following total knee arthroplasty: a preliminary report of a randomized, double-blind, parallel-group, placebo-controlled, multicentre trial. Clin Drug Investig. 2011 Dec 1;31(12):877-82. doi: 10.1007/BF03256925. PubMed 21971213 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Sep 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2008
First posted
May 21, 2008
Start
Sep 2007
Primary completionActual
Sep 2008
CompletionActual
Dec 2008
Last update
May 4, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00681356
Lead sponsor
Anesiva, Inc.
First posted
May 21, 2008
Start date
Sep 2007
Primary completion
Sep 2008
Completion
Dec 2008
Last update
May 4, 2009

Study contacts

Shaun Comfort, MD
study director · Anesiva, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion